Brain Tumors (Meningiomas)

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    PDGFR Overexpression Unknown Imatinib (BCR-Abl/cKIT/PDGFR inhibitor):
    • Phase 2, with hydroxyurea: SD at 6 mo 67% (30)
    EGFR Overexpression  40 Erlotinib or gefitinib (EGFR inhibitors):
    • Phase 2: PFS at 6 mo 29% (irrespective of drug) (31)
    VEGFR Expression 100 Bevacizumab (VEGF inhibitor):
    • Retrospective analysis: RR 29% of tumors (duration 3.7 mo), PFS at 6 mo 93%, PFS at 12 mo 62% (32)
    Other topics in Targets by Organ Site